Y-mAbs Therapeutics (YMAB) Revenue Breakdown: Q2 2025 Business & Regional Performance
Y-mAbs Therapeutics (YMAB) reported total revenue of 19.52M USD in Q2 2025, with its core business segment Product contributing 97.44%. Regionally, United States remained the largest market, accounting for 75.26% of total revenue. Explore Y-mAbs Therapeutics's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.